Albumin

Albumin

Global Albumin Market to Reach US$1.2 Billion by 2030

The global market for Albumin estimated at US$904.1 Million in the year 2023, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2023-2030. Human Serum Albumin, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$902.4 Million by the end of the analysis period. Growth in the Recombinant Albumin segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$236.4 Million While China is Forecast to Grow at 6.3% CAGR

The Albumin market in the U.S. is estimated at US$236.4 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$260.8 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Albumin Market - Key Trends & Drivers Summarized

Why Is Albumin Such a Vital Protein in Healthcare?

Albumin is a crucial protein produced by the liver, essential for maintaining blood volume and pressure by keeping fluid in the bloodstream. It also plays a key role in transporting hormones, vitamins, and drugs. In healthcare, albumin is widely used in the treatment of conditions such as liver diseases, burns, shock, and during surgeries to manage hypovolemia (low blood volume). Its broad therapeutic applications extend to drug delivery systems and vaccine formulations, further establishing its critical role. The widespread availability of recombinant and plasma-derived albumin has enhanced its accessibility, particularly in emergency medicine and critical care scenarios.

What Technological Innovations Are Shaping the Albumin Market?

The albumin market is witnessing significant growth due to advancements in production methods. Recombinant DNA technology has enabled the production of albumin that is free from pathogens, ensuring a higher safety profile for patients. This technology has reduced reliance on human plasma, mitigating risks associated with plasma shortages or contamination. Furthermore, researchers are exploring novel applications of albumin in drug delivery systems, where it enhances the efficacy of cancer drugs and extends their half-life. These technological innovations are driving the demand for albumin, particularly in the pharmaceutical and biopharmaceutical sectors.

How Are Global Healthcare Trends Impacting Albumin Demand?

The demand for albumin has seen a consistent rise due to increasing liver diseases, particularly cirrhosis, and an aging global population susceptible to hypovolemia and related conditions. The growing number of surgeries, trauma cases, and burn injuries is also driving albumin usage in critical care. Furthermore, the use of albumin in emerging applications such as vaccine formulations, especially in the wake of global vaccination campaigns, is pushing the boundaries of its market. As healthcare systems worldwide focus on improving emergency and trauma care, the need for albumin is set to increase, particularly in developing regions with expanding healthcare infrastructure.

What Factors Are Driving the Growth of the Albumin Market?

The growth in the albumin market is driven by several factors, including the increasing prevalence of chronic liver diseases and the expanding applications of albumin in therapeutic and biopharmaceutical sectors. The rise in surgeries and trauma cases is also a significant driver, necessitating albumin use in managing blood volume and pressure. Technological advancements in recombinant albumin production have improved its availability and safety, further boosting demand. Additionally, the growth of biopharmaceuticals and drug delivery systems, where albumin plays a vital role, is contributing to its rising market prominence.

Select Competitors (Total 14 Featured) -

• Albumedix Ltd.
• Albumin Bioscience
• Biotest AG
• CSL Behring
• Grifols International SA
• HiMedia Laboratories Pvt. Ltd.
• InVitria
• Medxbio Pte. Ltd.
• MilliporeSigma
• Octapharma AG
• RayBiotech, Inc.
• Seracare Life Sciences, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.